Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer

Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer

Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference

Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022

Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Annual Meeting

Aileron Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

Aileron Expands Management Team with Appointment of Christopher Zergebel As Vice President, Program Management and Clinical Operations

Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth Conference

Aileron Therapeutics Provides Business Update and Outlines 2022 Strategic Priorities to Deliver Key Milestones